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Abstract 
Endocrine-disrupting chemicals (EDCs) are a broad class of molecules present in our 
environment that are suspected to cause adverse effects in the endocrine system by interfering 
with the synthesis, transport, degradation or action of endogenous hormones. Humans are 
generally exposed to low doses of pollutants, and current researches aim at deciphering the 
mechanisms accounting for the health impact of EDCs at environmental concentrations. Here, 
we review different mechanisms through which EDCs might alter hormonal functions by 
interfering with the nuclear receptors and related pathways, including extranuclear signalling 
by membrane-bound receptors mediating rapid non-genomic responses, and the aryl 
hydrocarbon receptor (AhR).
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1. Introduction
Endocrine-disrupting chemicals (EDCs) are exogenous substances that interfere with the 
function of hormonal systems and produce a range of developmental, reproductive, 
neurological, immune or metabolic diseases in humans and wildlife [1-3]. Many EDCs are 
man-made chemicals produced by industry and released into the environment, but some 
naturally occurring EDCs can also be found in plants or fungi. The group of molecules acting 
as EDCs is highly heterogeneous and comprises compounds that are often distantly related to 
endogenous ligands in terms of size or chemical structure. This group contains substances as 
chemically different as bisphenols, phthalates, parabens, dioxins, alkylphenols, organotins, 
polychlorinated biphenyls, perfluoroalkyls, or benzophenones, as well as natural compounds 
such as the phytoestrogens genistein, daidzein or the mycoestrogen zearalenone. Since 
humans and wildlife are simultaneously and chronically exposed to low doses of multiple 
contaminants, understanding the molecular mechanisms underlying the physiological 
consequences of exposure to environmentally relevant concentrations of EDCs is a major 
challenge [4]. EDCs can affect the endocrine systems of an organism in a wide variety of 
ways. These include mimicking natural hormones, antagonizing their action or modifying 
their synthesis, metabolism and transport. As of today, most of the reported harmful effects of 
EDCs are attributed to their interaction with nuclear or extranuclear receptors that 
respectively function as transcriptional regulators in the nucleus such as the members of the 
nuclear receptors (NRs) superfamily [5,6] and the aryl hydrocarbon receptor (AhR) [7], or 
mediate rapid non-genomic responses, for instance, the membrane-associated nuclear 
receptors (mbNRs) [8] and the G protein-coupled receptor (GPCR) GPR30/GPER [9]. Herein, 
we review the main structural and molecular mechanisms used by EDCs to alter these 
signaling pathways and contribute to the etiology of several diseases.
32. Nuclear receptors are primary targets of EDCs
The 48 human NRs control a plethora of biological processes such as development, organ 
homeostasis, metabolism, immune function, or reproduction [10,11]. As a consequence, 
inappropriate exposure to EDCs, can cause proliferative reproductive and metabolic disorders, 
including hormonal cancers, infertility and obesity. Most of the studies on EDCs have 
originally focused on NRs involved in reproductive processes, in particular the estrogen (ER 
and ER) and the androgen (AR) receptors. However, mounting data reveal that most NRs are 
potential targets of EDCs. Among NRs, endogenous ligands have been identified for 24 
family members. These receptors are ligand-dependent transcription factors that respond 
directly to a large variety of hormonal and metabolic substances that are hydrophobic, lipid 
soluble, and of small size (e.g. retinoic acid or estradiol). The other class of NRs is the group 
of so-called orphan receptors, for which regulatory ligands are still unknown or may not exist. 
The transcriptional activity of orphan receptors is thus regulated by post-translational 
modifications or cell-specific expression of coregulatory proteins, and eventually by 
pharmacological or environmental chemicals, as for instance the estrogen related receptor γ 
(ERRγ) which has no endogenous ligand but is one of the main targets of bisphenol-A (BPA) 
[12]. All NR proteins exhibit a characteristic modular structure that consists of five domains 
(Fig. 1) [13]. The DNA-binding domain (DBD) is the most highly conserved domain and 
encodes two zinc finger modules. The ligand binding domain (LBD) is less conserved and 
mediates ligand binding, dimerization, and hosts a ligand-dependent transactivation function, 
termed AF-2 which corresponds to transcriptional coregulator interaction surfaces that are 
modulated by ligands. The remaining domains are the N-terminal region containing a cell- 
and promoter specific transactivation function termed AF-1, the central hinge region linking 
4the DBD and LBD, and the C-terminal region that is not present in all receptors and whose 
function is poorly understood. 
2.1 Genomic actions of nuclear receptors
NRs may act either as repressors or activators of gene transcription depending on their ligand-
binding status that in turn determines the ability of DNA-bound receptors to recruit 
coregulators to target gene promoters (Fig. 2). Coactivators and corepressors are large groups 
of proteins with a varied range of activities and enzymatic functions that contribute to 
transcription regulation by NRs and many other transcription factors, including AhR. 
Coactivators contribute to the enhancement of transcription by acetylating histones, a process 
that plays an important role in the opening of chromatin during transcription activation, 
whereas corepressors display the opposite activity by recruiting histone deacetylases 
(HDACs). Coactivator recruitment is usually ligand-dependent, whereas corepressors interact 
in most cases with unliganded receptors. In the absence of the cognate ligand, some NRs are 
located in the nucleus, bind to the DNA response elements of their target genes, and recruit 
corepressors, while others are located in the cytoplasm in an inactive complex with 
chaperones (Fig. 2). Ligand binding induces major structural alterations of the receptor LBDs 
leading to (i) destabilization of corepressor or chaperone interfaces, (ii) exposure of nuclear 
localization signals to allow nuclear translocation and DNA binding of cytoplasmic receptors, 
and (iii) recruitment of coactivators triggering gene transcription through chromatin 
remodelling and activation of the general transcription machinery.
2.2 A structural view of the interaction between nuclear receptors and EDCs
The LBD of NRs is composed of a conserved core of 12 -helices (H1 to H12) and a short 
two-stranded antiparallel -sheet (s1 and s2), arranged into a three-layered sandwich fold 
(Fig. 3A). This arrangement generates a mostly hydrophobic cavity, referred to as the ligand-
binding pocket (LBP), which can accommodate the cognate ligand. In hormone-bound LBD 
5structures, the LBP is sealed by helix H12, thus generating a hydrophobic binding groove for 
short LxxLL helical motifs (L stands for leucine and x for any amino acid) found within 
coactivators. Biochemical and cell-based assays have revealed that EDCs bind to NRs with 
affinities ranging from sub-nanomolar to high micromolar values and structural analyses have 
revealed some mechanisms by which compounds structurally and chemically unrelated to 
physiological ligands can bind to NRs at environmentally relevant concentrations [14-16]. 
Representative examples are the binding of -zearalanol (α-ZA) to ER, the covalent 
interaction of various chemicals with the retinoid X receptor (RXR), the peroxisome 
proliferator-activated receptor γ (PPARγ) and the xenobiotic receptor PXR, or the cooperative 
binding of two chemicals to PXR and PPARγ. Even though the mycoestrogen α-ZA (Fig. 1) is 
not a steroidal compound, it recapitulates the key interaction networks observed between the 
residues of the ER LBP and the endogenous hormone 17-estradiol E2 (Fig. 3B). As such, 
α-ZA appears as an E2 mimic that binds to its target receptor at sub-nanomolar concentrations 
[17]. In contrast, compounds of the organotin family such as the tributyltin (TBT, Fig. 1) bind 
with much avidity to many NRs through a mechanism that is totally different from those used 
by the natural or pharmacological ligands of these receptors. Indeed, the nanomolar affinity of 
organotins for NRs arises from the formation of a strong covalent bond formed between the 
tin atom of the chemical and the sulfur atom of a cysteine residue contained in the LBP of the 
receptors [14] (Fig. 3C). Beside tin compounds, many bioactive chemicals such as pesticides 
or drugs contain chemical groups that are prone to forming such covalent links with reactive 
cysteine residues, thereby insuring high affinity binding of the compounds. Structural studies 
have revealed that the insecticide fipronil and the herbicide pretilachlor bind to and activate 
PXR via this mechanism (our unpublished data). It is thus very likely that part of the low dose 
effects of a number of environmental compounds can be explained by their covalent 
interaction with the dozen NRs containing a cysteine residue in their LBP. Compared to 
6binding sites located at the surface of proteins, the buried and mostly hydrophobic cavity 
provided by NRs probably offers an environment allowing a residence time long-enough to 
let the chemical reaction to occur. Finally, recent studies have shown that NR LBPs are more 
conformable than previously thought and can eventually accommodate several compounds 
simultaneously [18-22]. In some instances it has been shown that the compounds not only 
bind concomitantly to the receptor, but they do so cooperatively, i.e. the binding of one 
molecule promotes high affinity binding of the second, with synergistic effects on receptor 
function. Notably, the contraceptive 17α-ethinylestradiol (EE2, Fig. 1) and the persistent 
organochlorine pesticide trans-nonachlor (TNC, Fig. 1), both exhibiting low affinity and 
efficacy when studied separately, where shown to bind and activate the receptor PXR at much 
lower concentration when used in combination [20] (Fig. 3D). 
2.3 Non-genomic actions of nuclear receptors
Beside their interference with the genomic pathways of NRs, EDCs have also been shown to 
interact with the membrane-associated fraction of these receptors (Fig. 2). Indeed, it is now 
well accepted that a small amount of NRs (a few percent) are positioned at the membrane 
(mbNRs) as previously shown for ER and , and for many other NRs such as the 
progesterone, the androgen, the thyroid hormone or the vitamin D receptors [23-26]. As for 
ER, the receptor is directed to the plasma membrane/caveloae via palmytoylation of an 
internal cysteine residue (C447) that is located in the LBD. Once localized in caveolae rafts, 
ligand-bound mbER is depalmytoylated and interacts with and activates various G and 
G/γ proteins within seconds, thereby triggering a cascade of signal transduction including 
cAMP production, calcium mobilization, ion channel activation, endothelial nitric oxide 
synthase and multiple kinases (ERK and PI3K) activation [27]. It is interesting to note that 
mice expressing ER mutated in this cysteine 447 (cysteine 451 in mice) are sterile (both 
males and females) and present differences in E2 vascular actions, such as abrogation of 
7endothelial repair and eNOS phosphorylation. In contrast, other responses like endometrial 
proliferation are similar to will-type mice [28]. These membrane-localized ERs are thought to 
mediate the rapid non genomic effects of natural (E2) or environmental estrogens (BPA or 
alkylphenols) outside the nucleus [28,29]. Because the membrane-associated receptors are 
often the same proteins as their nuclear counterparts, one can make the assumption that 
compounds bind to the two receptor forms with the same mechanisms and thus similar 
binding affinities. However, it is not excluded that the membrane environment modifies the 
thermodynamics of the interactions with an impact on the ligand-binding properties of the 
receptor. Furthermore, it has been postulated that, in contrast to the nuclear pathway requiring 
ER-ligand complexes of sufficient lifetime to induce a long series of molecular events 
including dissociation from heat shock proteins, translocation, dimerization and DNA 
binding, recruitment of coregulators, alteration of chromatin architecture and finally 
transcription initiation, the extranuclear signalling pathway involving the rapid triggering of 
kinase cascades could be activated by ER-ligand complexes with shorter half-life [30]. In this 
context, one can note that the low binding affinity constant (Kd) of compounds such as 
bisphenols and alkylphenols generally results from a high dissociation rate constant (Koff) so 
that their complexes with ER feature short lifetimes [31]. Although this hypothesis needs 
further investigations, it could explain that EDCs with about 10,000-fold less affinity than E2 
for ERs can activate the extranuclear-initiated signaling pathway preferentially over the 
nuclear pathway.
3. The aryl hydrocarbon receptor
3.1 AhR structure and function
The Aryl hydrocarbon Receptor (AhR), also known as the dioxin receptor, is a ligand-
dependent transcription factor belonging to the basic helix-loop-helix (bHLH) PER-ARNT-
SIM (PAS) protein family that binds to DNA following formation of a heterodimer with the 
8AhR-nuclear translocator protein (ARNT) [32,7]. Although not members of the NR family, 
AhR and ARNT display structural and functional similarities with NRs such as a molecular 
organisation in four major domains including a DBD and LBD, or a transcriptional activity 
that is regulated by the presence of ligands and coregulators (Fig. 1). The N-terminal bHLH 
domain is involved in DNA recognition. The PAS domain exists as a tandem of two domains, 
PAS-A and PAS-B, respectively, each encompassing around 50 amino acids. The bHLH and 
PAS-A domains of both AhR and ARNT dimerize to form a stable DNA-bound heterodimer. 
In AhR, the PAS-B domain is responsible for ligand binding. The C-terminal part of the 
protein also includes a transcriptional activation domain (TAD). Several multi-domain crystal 
structures of AhR-ARNT heterodimers have been recently reported providing insights onto 
the modes of DNA binding and dimerization of the complex [33,34]. These structures are 
characterized by sophisticated domain interplay and reveal a highly intertwined architecture 
that bind to DNA via the positively charged residues of the bHLH domains. None of the 
structures reported yet contain the PAS-B region of AhR so that the detailed mechanisms of 
ligand-binding and protein activation remain largely elusive. However, together with the 
extended interdomain interfaces, the high structural dynamics of the AhR PAS-A domain 
suggest an allosteric communication route to mediate ligand-induced changes in the PAS-B 
domain to the DNA-binding bHLH domains, the C-terminal TAD or the nuclear localization 
sequence (NLS). AhR binds a selection of different endogenous ligands including tryptophan-
derived metabolites and several dietary indoles, and is involved in many cellular processes 
including cell proliferation and differentiation, immune response, inflammation and circadian 
rhythm regulation [7]. While AhR also functions as a sensor of exogenous chemicals and 
promotes metabolic clearance through the induction of metabolizing enzymes such as 
CYP1A1 and CYP1B1 upon activation by external compounds, it is known to mediate most 
of the toxic effects of a range of environmental contaminants such as polyaromatic 
9hydrocarbons (PAHs) and dioxins. These toxic effects are numerous and include 
teratogenicity, immunosuppression, metabolic and endocrine disruption, skin toxicity and 
cancer. In the absence of ligand, AhR resides in the cytosolic compartment of the cell bound 
to a molecular chaperone complex containing Hsp90 and XAP2 (Fig. 2). Upon ligand binding 
AhR translocates from the cytosol to the cell nucleus where it forms a heterodimer with 
ARNT. The AhR-ARNT complex recognizes specific sequences of DNA called xenobiotic 
responsive element (XRE) in the promoter region of the target genes and activates 
transcription of these genes via the recruitment of transcriptional coactivators. The activity of 
the AhR-ARNT complex is negatively modulated by proteasomal degradation and the AhR 
repressor (AhRR) that interacts with ARNT and forms an AhRR-ARNT heterocomplex down 
regulating AhR signalling. In addition to its direct interaction with target gene promoters, 
AhR accomplishes some of its regulatory functions by modulating the activity of other 
transcriptions factors including ERs, AR, and many others [35]. The liganded AhR-ARNT 
heterodimer modulates estrogen and androgen signaling positively by physically associating 
with unliganded ERs and AR and bringing transcriptional coactivators to the promoters of 
these receptors [36]. In contrast, in presence of estrogens and androgens, the liganded AhR-
ARNT represses estrogen and androgen mediated transcription by targeting ERs and AR to 
the Cul4B-based ubiquitin ligase complex for proteosomal degradation [37]. Thus it appears 
that AhR acts both as a transcription factor and as an ubiquitin ligase component to mediate 
different signaling pathways [35]. 
3.2 AhR ligands and ligand binding
Although AhR was originally discovered as a primary target of the toxic dioxin (2,3,7,8-
tetrachloro-dibenzo-p-dioxin, TCDD, Fig. 1), it is now recognized that AhR is able to respond 
to hundreds of chemically diverse endogenous, dietary and environmental compounds, a 
number of these compounds interacting with the receptor at (sub)nanomolar concentrations 
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[38]. AhR ligands include polychlorinated dibenzo-p-dioxins, dibenzofurans (Fig. 1), 
polychlorinated biphenyls (e.g. PCB126, Fig. 1), polycyclic aromatic hydrocarbons (PAHs) as 
benzo(a)pyrene (BaP) and related PAHs compounds, including 3-methylcholanthrene (3MC) 
and -naphtoflavone. Dietary compounds (3,3’diindoylmethane and indolo(3,2)carbazole) 
and endogenous metabolites, such as indirubin and 6-formyindolo(3,2)carbazole (FICZ, Fig. 
1) are also known to act as AhR ligands. In addition to their high affinity, some AhR ligands 
such as dioxins are very resistant to metabolism, which appears to confer a greater toxicity 
when compared to that of compounds such as BAP or 3MC which are rapidly metabolized by 
CYP1A1 [38]. In contrast, the mechanism of carcinogenicity of some PAHs includes the 
production of highly reactive genotoxic metabolites. While no structure of the AhR LBD has 
been reported yet, molecular modelling using the structures of closely related PAS domains 
has suggested some molecular features accounting for its ligand-binding promiscuity and 
specificity [39]. In particular, mutational analysis, molecular modelling and molecular 
dynamics simulations have identified residues that control ligand preferences and the high 
dynamics of some structural elements rendering the AhR PAS-B domain malleable [40-44]. 
Interestingly, flexibility of some regions of the LBD is also a characteristic feature of the NR 
PXR which is another major chemical sensor known to induce the expression of 
detoxification proteins such as metabolizing enzymes and transporters upon activation by a 
broad range of chemicals [45]. PXR contains several loops clustering at the bottom of the 
LBD that confer a high plasticity allowing the ligand binding pocket of the receptor to adopt 
different shapes according to the bound ligands. Three of these flexible elements are found in 
a PXR-specific sequence of approximately 60 residues inserted between helices H1 and H3 
that display high thermal B factors (indicating structural mobility) or are completely 
disordered as observed in the crystal structures. However, a striking difference between the 
two receptors is that AhR is recognized by a number of high affinity ligands like TCDD or 
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FICZ (with nanomolar affinities), whereas PXR is essentially bound by compounds with 
affinities in the micromolar to sub-micromolar range [38]. One potential explanation for this 
difference may reside in the size of the binding cavity of the two receptors. Indeed, while 
PXR displays the largest binding pocket among all NRs with experimentally-determined 
volumes ranging from 1280 to 1600 Å3 depending on the bound compound, homology 
modelling of the PAS-B domain of AhR suggests a volume of the binding pocket in the range 
300–400 Å3 [46]. As a consequence, ligands generally occupy only a small fraction of the 
PXR binding pocket so that compounds appear to interact loosely with the residues lining the 
cavity, whereas the smaller pocket size of AhR may result in tighter contacts and a more 
stable ligand-bound complex. Another difference between the two proteins is that AhR is 
more easily antagonized than PXR. Indeed, a number of potent AhR antagonists have been 
discovered a while ago [47-49], whereas the first PXR antagonist has been reported only very 
recently [50,51]. This observation is consistent with a smaller and more constrained binding 
pocket in AhR.
4. G protein-coupled receptor 30
The G protein-coupled receptor 30 (GPR30) also referred to as G protein-coupled estrogen 
receptor (GPER) was also proposed to act as a non-classical estrogen receptor localized at the 
plasma membrane or the endoplasmic reticulum [52,53]. Originally, GPR30 was identified as 
an orphan receptor belonging to the family of 7-transmembrane-spanning GPCRs. Later on, 
several studies reported the activation of GPR30 by natural, environmental and 
pharmaceutical estrogens and antiestrogens (for a review see [54]), leading to its designation 
as GPER. However contradictory results concerning the ability of this receptor to bind 
estrogens have been reported. Binding of E2 and several xenoestrogens to GPR30 was 
observed by some laboratories [53] whereas others failed to detect any interaction [55,56]. 
Finally, the transgenic KO for GPR30 do not display phenotypes that result from estrogen 
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depletion suggesting that GPR30 is not a direct mediator of estrogen effects but could be 
rather a collaborator in non-nuclear functions of the nuclear ER [57,58]. Several selective 
GPR30 agonists and antagonists have been recently identified which will probably help 
characterizing the role GPR30 in these toxic effects in the future [9].
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Figure captions
Fig. 1. Nuclear receptors, AhR and GPR30 are the main known targets of endocrine 
disruptors. Structural organisation of proteins, and chemical structures of the associated EDCs 
mentioned in this review (EE2 = ethinylestradiol; TNC = trans-nonachlor; TBT = tributyltin; 
TCDD = 2,3,7,8-tetrachloro-dibenzo-p-dioxin; PCB-126 = polychlorinated biphenyl 126; 
FICZ = 6-formyindolo(3,2)carbazole).
Fig. 2. EDCs targeted cellular pathways. 1 The genomic pathways of nuclear receptors (NRs) 
and AhR, 2 the extranuclear signalling pathway of membrane-bound NRs (mbNR), and 3 the 
G protein-coupled receptor 30 (GPER/GPR30) pathway.
Fig. 3. Different binding modes of EDCs observed with NRs. A. Conserved 3D-structure of 
the ligand binding domain of nuclear receptors (here, ERα in complex with estradiol, PDBid = 
3UUD). Close up view of the ligand binding pockets of B. ERα in complex with α-zearalanol 
(PDBid = 4MG8), C. RXR in complex with TBT (PDBid = 3E94), and D. PXR in complex 
with EE2 and TNC (PDBid = 4X1G).
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